Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress

Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218

Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202

Argo Biopharma Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE

Argo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer